Targeted Boron Neutron Capture Therapy Using Polymalic Acid Derived Nano-Boron to Treat Glioblastoma

Area of Science:

• Oncology
• Nanomedicine
• Radiotherapy

Background:

• Glioblastoma multiforme (GBM) remains a challenging brain cancer with limited treatment advancements.
• Conventional radiotherapy (RT) for GBM is hampered by radio-resistance and dose-limiting toxicities.
• Boron neutron capture therapy (BNCT) offers targeted tumor irradiation but requires selective boron uptake.

Purpose of the Study:

• To develop an innovative nanomedicine-based strategy for enhanced boron delivery in GBM.
• To improve the efficacy of Boron Neutron Capture Therapy (BNCT) for glioblastoma multiforme.
• To overcome limitations of current GBM treatments and enhance patient outcomes.

Main Methods:

• Utilized polymalic acid (PMLA) as a nanocarrier for boron-10 delivery.
• Incorporated isotopically enriched 4-boronophenylalanine (BPA) for boron-10 loading.
• Functionalized nanoconjugates with Angiopep-2 (AP2) peptide for blood-brain barrier penetration and tumor targeting.

Main Results:

• Developed a novel nanodrug (Nano-Boron) capable of carrying multiple boron-10 molecules per nanoconjugate.
• The PMLA platform facilitates high boron-10 loading, increasing intracellular boron concentration.
• Angiopep-2 peptide enhances targeted delivery to brain tumors across the blood-brain barrier.

Conclusions:

• The novel nanodrug demonstrates potential for effective boron delivery in GBM.
• This approach may significantly enhance the efficacy of BNCT for glioblastoma treatment.
• The developed nanomedicine holds promise for improving survival and quality of life in GBM patients.